Bristol-Myers Squibb reached a $19.5 million settlement Thursday on its off-label promotion of Abilify, an anti-psychotic that was originally designed to treat schizophrenia. Updates ... Abilify has ...

The FDA has issued a public health advisory concerning the use of antipsychotic drugs after finding that elderly patients taking the medications were more likely to die than those receiving a placebo.

Abilify Abilify is FDA approved to treat schizophrenia, ... Abilify received a black box warning label for inducing suicidal feelings in children. In 2009, sales of the drug reached $4 billion.

The Food and Drug Administration ordered new warnings on antipsychotic drugs, alerting physicians to a higher death rate when the medicines are prescribed f or dementia in elderly patients.

Those drugs -- which include Abilify, from Bristol-Myers Squibb Co and Otsuka Pharmaceutical Group, and Zyprexa, from Eli Lilly and Co -- already carry a boxed warning about such risk.

April 13, 2004 — Bristol-Myers Squibb has notified healthcare professionals of a revision to the warnings section of labeling for aripiprazole (Abilify), describing the potential increased risk ...

WASHINGTON, June 16 (Reuters) - Older, conventional antipsychotic medications should carry a "black box" warning about an increased risk of death in some elderly people being treated for dementia ...